HLB Pep Co., Ltd. (KOSDAQ:196300)
4,215.00
-45.00 (-1.06%)
At close: Sep 3, 2026
HLB Pep Revenue
HLB Pep had revenue of 1.26B KRW in the quarter ending June 30, 2026, with 2.22% growth. This brings the company's revenue in the last twelve months to 5.54B, up 14.70% year-over-year. In the year 2025, HLB Pep had annual revenue of 4.96B, down -20.34%.
Revenue (ttm)
5.54B
Revenue Growth
+14.70%
P/S Ratio
7.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
40.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.96B | -1.27B | -20.34% |
| Dec 31, 2024 | 6.23B | 618.09M | 11.02% |
| Dec 31, 2023 | 5.61B | -3.05B | -35.23% |
| Dec 31, 2022 | 8.66B | -1.60B | -15.63% |
| Dec 31, 2021 | 10.27B | 1.75B | 20.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| J2KBIO | 43.90B |
| Eutilex.Co.,Ltd | 7.71B |
| QuadMedicine | 7.14B |
| Parataxis Korea | 1.59B |
| Kainos Medicine | 1.40B |
| NovMetaPharma | 1.30B |
| Quratis | 1.10B |